To the full analysis
APT Medical stock: growth
688617.SSAPT Medical reported $387.5M in revenue for fiscal 2025, up 25.1% on the prior year, up 40.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
42.4%
per year from 2017 to 2025, per share 37.2%
Earnings (Annual rate)
48.6%
per year from 2017 to 2025, per share 43.2%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2017 | |
|---|---|---|
| Revenue | 40.1% | 42.4% |
| Revenue per share | 32.0% | 37.2% |
| Earnings | 49.3% | 48.6% |
| Earnings per share | 40.6% | 43.2% |
| Free cash flow | 46.0% | no data |
| Free cash flow per share | 37.6% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $22.97M | $5.17M | −$1.85M |
| 2018 | $36.26M | $3.23M | −$2.03M |
| 2019 | $60.58M | $12.38M | −$1.9M |
| 2020 | $71.9M | $16.61M | $15.6M |
| 2021 | $124.27M | $31.18M | $2.1M |
| 2022 | $182.36M | $53.69M | $33.63M |
| 2023 | $247.47M | $80.07M | $73.04M |
| 2024 | $309.8M | $100.95M | $13.97M |
| 2025 | $387.5M | $123.07M | $103.43M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 5 Jun 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.